These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 39116277

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, Pérez de José A, López I, Fernández L, Pérez Gómez V, Ávila A, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, Goicoechea de Jorge E, Caravaca F, Praga M, C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [Abstract] [Full Text] [Related]

  • 4. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
    Gonzalez Suarez ML, Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Aeddula NR, Pivovarova AI, Chewcharat A, Bathini T, Mao MA, Basu A, Cheungpasitporn W.
    Med Sci (Basel); 2020 Oct 21; 8(4):. PubMed ID: 33096866
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.
    Clin J Am Soc Nephrol; 2014 Nov 07; 9(11):1876-82. PubMed ID: 25341722
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C, Horinouchi T, Inoki Y, Ichikawa Y, Tanaka Y, Kitakado H, Kondo A, Sakakibara N, Nagano C, Yamamura T, Fujimura J, Kamiyoshi N, Ishimori S, Ninchoji T, Kaito H, Shima Y, Iijima K, Nozu K, Yoshikawa N.
    Pediatr Nephrol; 2024 Sep 07; 39(9):2679-2689. PubMed ID: 38662234
    [Abstract] [Full Text] [Related]

  • 9. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.
    Kumar A, Ramachandran R, Rawat A, Das R, Rayat CS, Kenwar DB, Sharma A, Gupta KL, Nada R.
    Clin Kidney J; 2021 Jan 07; 14(1):291-300. PubMed ID: 33564431
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.
    Nephrol Dial Transplant; 2018 Dec 01; 33(12):2260-2265. PubMed ID: 29370420
    [Abstract] [Full Text] [Related]

  • 13. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.
    Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S.
    J Am Soc Nephrol; 2014 May 01; 25(5):1110-7. PubMed ID: 24357668
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ.
    Pediatr Nephrol; 2022 Mar 01; 37(3):601-612. PubMed ID: 34476601
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pediatric C3 glomerulopathy: a 12-year single-center experience.
    Zahir Z, Wani AS, Gupta A, Agrawal V.
    Pediatr Nephrol; 2021 Mar 01; 36(3):601-610. PubMed ID: 33000324
    [Abstract] [Full Text] [Related]

  • 18. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
    Kumar A, Nada R, Ramachandran R, Rawat A, Tiewsoh K, Das R, Rayat CS, Gupta KL, Vasishta RK.
    J Nephrol; 2020 Jun 01; 33(3):539-550. PubMed ID: 31820418
    [Abstract] [Full Text] [Related]

  • 19. Characterization of C3 in C3 glomerulopathy.
    Sethi S, Vrana JA, Fervenza FC, Theis JD, Sethi A, Kurtin PJ, Zhang Y, Smith RJH.
    Nephrol Dial Transplant; 2017 Mar 01; 32(3):459-465. PubMed ID: 27507892
    [Abstract] [Full Text] [Related]

  • 20. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.
    Moog P, Jost PJ, Büttner-Herold M.
    BMC Nephrol; 2018 May 03; 19(1):106. PubMed ID: 29724174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.